{
    "Clinical Information": [],
    "Patent Information": [
        {
            "Patent No": "US 2023/0416797 A1",
            "Patent Link": "http://www.lens.org/lens/patent/US_2023_0416797_A1",
            "Patent Type": "Patent Application",
            "Publication Date": "2023-12-28",
            "Family Info": "JP2023548477A,EP4243844A1,CN116685204A,WO2022104321A1",
            "Patent Title": "MODULATING ANTIMICROBIAL PEPTIDE HALF-LIFE",
            "Abstract": "Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described."
        }
    ],
    "Sequence Information": {
        "DRAMP ID": "DRAMP00017",
        "Peptide Name": "Microbisporicin A1 (Bacteriocin)",
        "Source": "Microbispora corallina (Gram-positive bacteria)",
        "Family": "Belongs to the lantibiotic family (Class I bacteriocin)",
        "Gene": "Not found",
        "Sequence": "VTSWSLCTPGCTSPGGGSNCSFCC",
        "Sequence Length": "24",
        "UniProt Entry": "No entry found",
        "Protein Existence": "Protein level",
        "Biological Activity": [
            "Antimicrobial, Antibacterial"
        ],
        "Target Organism": "Human pathogens:L100 Staphylococcus aureus ATCC6538P (MIC≤0.13 μg/ml), L819 Staphylococcus aureus Smith ATCC19636 (MIC≤0.13 μg/ml), L1400 S. aureus MRSA (MIC≤0.13 μg/ml), L613 S. aureus MRSA (MIC≤0.13 μg/ml), L3798 S. aureus VISA (MIC=2 μg/ml), L3798 Staphylococcus epidermidis ATCC12228 (MIC≤0.13 μg/ml), L1729 Staphylococcus haemolyticus met-r (MIC=8 μg/ml), L49 Streptococcus pyogenes (MIC≤0.13 μg/ml), L44 Streptococcus pneumoniae (MIC≤0.13 μg/ml), L559 Enterococcus faecalis (MIC=1 μg/ml), L560 Enterococcus faecalis Van A (MIC=0.5 μg/ml), LA533 Enterococcus faecalis Van A (MIC=1 μg/ml), L568 Enterococcus faecium (MIC=2 μg/ml), L569 Enterococcus faecium Van A (MIC=1 μg/ml), LB518 E. faecium Van A (MIC=2 μg/ml), L884 Lactobacillus garviae (MIC=1 μg/ml), L148 Lactobacillus delbrueckii ATCC04797 (MIC=4 μg/ml), L3607 Clostridium perfringens ATCC13124 (MIC≤0.125 μg/ml), L4018 Clostridium difficile (MIC≤0.125 μg/ml), L4043 Clostridium butyricum (MIC≤0.125 μg/ml), Propionibacterium granulosum ATCC25564 (MIC=0.03 μg/ml), L1329 Propionibacterium acnes (MIC=0.5 μg/ml), Propionibacterium limphophylum ATCC27250 (MIC=0.015 μg/ml), L970 Haemophilus influenzae ATCC19418 (MIC=32 μg/ml), L76 Moraxella catarrhalis ATCC8176 (MIC=0.25 μg/ml), L1613 Neisseria meningitidis ATCC13090V (MIC=0.5 μg/ml), L997 Neisseria gonorrhoeae (MIC=0.25 μg/ml).",
        "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
        "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented",
        "Binding Target": "Not found",
        "Linear/Cyclic": "Cyclic",
        "N-terminal Modification": "Free",
        "C-terminal Modification": "Amidation and Cyclization",
        "Nonterminal Modifications and Unusual Amino Acids": "①There are five thioether intramolecular bridges which link Ala3 and Ala7, Ala8 and Ala11, Ala13 and Ala20, Ala18 and Ala23, respectively. ②The residue at position 2 is (Z)-2,3-didehydrobutyrine (Dhb). ③The residue at position 4 is chloro-tryptophan (ClTrp). ④The residue at position 5 is 2,3-didehydroalanine. ⑤The residue at position 8 is 2-Aminobutyric acid (Abu). ⑥The residue at position 14 is bis-hydroxylated proline.",
        "Stereochemistry": "L",
        "Structure": "Rich",
        "Structure Description": "Not found",
        "Helical Wheel Diagram": "",
        "PDB ID": "None",
        "Predicted Structure": "There is no predicted structure for DRAMP00017.",
        "Formula": "C95H144N26O34S5",
        "Absent Amino Acids": "ADEHIKMQRY",
        "Common Amino Acids": "CS",
        "Mass": "2354.64",
        "PI": "5.47",
        "Basic Residues": "0",
        "Acidic Residues": "0",
        "Hydrophobic Residues": "4",
        "Net Charge": "0",
        "Boman Index": "-6.92",
        "Hydrophobicity": "0.333",
        "Aliphatic Index": "28.33",
        "Half Life": "Mammalian:100 hourYeast:>20 hourE.coli:>10 hour",
        "Extinction Coefficient Cystines": "5750",
        "Absorbance 280nm": "250",
        "Polar Residues": "18",
        "Function": "Microbisporicins A1 displayed similar antibacterial activity by selectively blocking peptidoglycan biosynthesis, leading to cytoplasmic accumulation of the UDP-linked precursor.",
        "PTM": "Microbisporicin A1 contains five ether rings",
        "Literature": [
            {
                "Title": "Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens.",
                "Pubmed ID": "18215770",
                "Reference": "Chem Biol. 2008 Jan;15(1)22-31.",
                "Author": "Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F.",
                "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=18215770"
            }
        ],
        "3D_Structures": []
    }
}